key: cord-0905411-tikvcang
authors: Gordon, Ph.D. Mollie M. Van; McCarthy, Ph.D. Kevin A.; Proctor, Ph.D. Joshua L.; Hagedorn, MBA Brittany L.
title: Evaluating COVID-19 reporting data in the context of testing strategies across 31 LMICs
date: 2021-07-23
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.07.042
sha: aa9f0e955819150c7e4461fffd9f472ff9314dfb
doc_id: 905411
cord_uid: tikvcang

BackgroundCOVID-19 case counts are the predominant measure used to track epidemiological dynamics and inform policy decision-making. Case counts, however, are influenced by testing rates and strategies, which have varied over time and space. A method to consistently interpret COVID-19 case counts in the context of other surveillance data is needed, especially for data-limited settings in low- and middle-income countries (LMICs). MethodsWe leverage statistical analyses to detect changes in COVID-19 surveillance data. We apply the pruned exact linear time change detection method for COVID-19 case counts, number of tests, and test positivity rate over time. With this information, we categorize change points as likely driven by epidemiological dynamics or non-epidemiological influences such as noise. FindingsHigher rates of epidemiological change detection are more associated with open testing policies than with higher testing rates. We quantify alignment of non-pharmaceutical interventions with epidemiological changes. LMICs have the testing capacity to measure prevalence with precision if they use randomized testing. Rwanda stands out as a country with an efficient COVID-19 surveillance system. Sub-national data reveal heterogeneity in epidemiological dynamics and surveillance. InterpretationRelying solely on case counts to interpret pandemic dynamics has important limitations. Normalizing counts by testing rate mitigates some of these limitations, and open testing policy is key to efficient surveillance. Our findings can be leveraged by public health officials to strengthen COVID-19 surveillance and support programmatic decision-making. FundingThis publication is based on models and data analysis performed by the Institute for Disease Modeling at the Bill & Melinda Gates Foundation.

Evidence before this study

We searched for articles on the current practices, challenges, and proposals for COVID-19 surveillance in LMICs. We used Google Scholar with search terms including "COVID surveillance." Existing studies were found to be qualitative, anecdotal, or highly location-specific.

We developed a quantitative method that makes use of limited information available from LMICs. Our approach improves interpretation of epidemiological data and enables evaluation of COVID-19 surveillance dynamics across countries.

Our results demonstrate the importance of open testing for strong surveillance systems, bolstering existing anecdotal evidence. We show strong alignment across LMICs between non-pharmaceutical interventions and epidemiological changes. We demonstrate the importance of considering sub-national heterogeneity of epidemiological dynamics and surveillance. and trajectory of the COVID-19 outbreak and to control its progression using 5 non-pharmaceutical interventions (NPIs). Disease surveillance has mostly 6 relied on case counts to inform public health policies (WHO 2020). There 7 has not, however, been a robust evaluation of case counts as a metric for 8 epidemiological dynamics, nor the varied surveillance approaches used to 9 track disease trajectories. 10 Case-based surveillance systems have known weaknesses, including the strong 11 influence of testing rates, which vary widely across space and time (Haider 12 et al. 2020) . Case counts can be inconsistently measured, testing capacity 13 limited, and eligibility policies variable. It is critical to understand the lim-14 itations of available data and to identify metrics that are robust to these 15 challenges, particularly for low-and middle-income countries (LMICs). 16 There is general recognition that surveillance system performance can be 17 a challenge in LMICs, and that understanding disease surveillance is key 18 to system improvement and production of representative data (Petti et al. 19 2006). Existing efforts to evaluate LMIC surveillance systems, however, are 20 largely qualitative, country-specific, or based on commentary (Ibrahim 2020; 21 Farahbakhsh et al. 2020; Alwan 2020). Further, most national-level studies 22 of NPI impacts focus on high-income countries, but there is evidence that 23 these insights cannot be readily generalized to LMIC settings (Brauner et al. 24 2020; Flaxman et al. 2020; Hsiang et al. 2020; Dehning et al. 2020; Chen 25 et al. 2020; Islam et al. 2020; Haider et al. 2020) . This leaves an important 26 knowledge gap in understanding how to evaluate and interpret COVID-19 27 epidemiological data from LMICs. 28 To address the gap in systematic interpretation and evaluation methods, we 29 leverage statistical analysis techniques to detect changes in underlying prop-30 erties of COVID-19 time series surveillance data across 31 LMICs. With this 31 information, we categorize detected change points as likely driven by epi-32 demiological changes or non-epidemiological influences such as noise. This 33 provides a quantitative and automated approach to analyzing epidemiolog-34 ical surveillance data. We make use of imperfect information despite data 35 weaknesses, deriving insights from information available in LMICs that may 36 otherwise be overlooked. The approach is fast and highly portable, well 37 suited to looking across countries, and has minimal data requirements. 38 In this article, we first present the methods for our analysis, including the 

The methods are outlined in Figure 1 

We use national-level case and testing data as well as records on national 51 policies for testing and NPIs (Roser et al. 2020; Hale et al. 2020 Change detection identifies changes that may be related to data quality, 91 stochasticity, and testing dynamics, in addition to epidemiological changes. 3.2. Testing rates and policies impact how surveillance measures should be 133 interpreted.

We illustrate the relevance of testing rates and the influence of testing pol- 3.4. Change detection rates and NPI alignment frequency vary across LMICs.

173 Figure 6A shows the wide variation of epidemiological change detection rates 174 across LMIC countries, with Rwanda the highest and Ethiopia the lowest.

The percentage of NPIs that are aligned with a detected epidemiological 176 change is shown in Figure 6B , again led by Rwanda. Rwanda performs well 11.6% and a standard deviation of 3.64% (gray violin distributions, Figure   194 7). When analyzed by country, nearly all NPI alignment rates are either 195 higher or lower than the random date distributions (cyan circles, Figure 7 ). 3.6. National-level results obscure sub-national heterogeneity in epidemiolog-205 ical dynamics and surveillance.

To investigate sub-national heterogeneity, we conduct the same analyses as 207 above, but at the province level in South Africa. Figure 8A shows substantial only.

We select three edge cases from the scatter plot in Figure 8A Deaths per thousand people shown on the right y-axis: excess mortality in black; COVID-19-confirmed deaths in brown.

We have demonstrated a standardized and quantitative approach to ana-228 lyzing epidemiological surveillance time series that can be automated for 229 improved interpretation and comparison between countries. We find that in- In a sensitivity analysis of our novel parameterization approach, however, 265 we find that Rwanda remains the leader in surveillance system performance, 266 regardless of the parameterization choice.

Results from this analysis highlight that surveillance data must be used care- Weekly cases, testing, and death data are interpolated using a cubic spline.

All daily cases, testing and death data are smoothed using a centered seven- To evaluate the influence of penalty selection on our analysis results, we con- Surveillance metrics:

Cases total = SARS -CoV -2

Cases detected = T ests * Cases Eligible P ositivity = Cases detected T ests = Cases Eligible

Symptomatic testing:

Cases detected sympt = T ests sympt * Cases sympt CLI P ositivity sympt = Cases sympt CLI Random testing:

Cases detected rand = T ests rand * Cases total P opulation P ositivity rand = Cases total P opulation = P revalence are divided by NPI counts on the diagonal. Bottom: Correlation score and frequency of aligned NPIs by type. Correlation score is the sum of the correlation matrix along the y-axis, normalized to one. Normalized frequency is the count of aligned NPI by type normalized to one.

SARS -CoV -2 = SARS -CoV -2 asympt + SARS -CoV -2 sympt

Non-SARS -CoV -2 = Non-SARS -CoV -2 non-sympt + Non-SARS -CoV -2 sympt non-CLI + Non-SARS -CoV -2 sympt CLI Testing components: Eligible rand = P opulation = SARS -CoV -2 + Non-SARS -CoV

Eligible sympt = CLI = Non-SARS -CoV -2 sympt CLI + SARS -CoV -2 sympt

Appendix A.4. Parameterization sensitivity analysis